Table 1.
Baseline characteristics of included studies.
| Author (year) | Country | Cases | Cancer stage | Follow-up (mean) | Sample | VEGF assay | Cut-off | Field | Statistical method | NOS/REMARK item score | Outcome investigated |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cheng et al. (52) | China | 50 | I–IV | Mean 32.6 months | Tissue | IHC | Score | 400× | M | 8/14 | OS |
| Zhang et al. (40) | China | 96 | I–IV | Mean 3 years | Tissue | IHC | >5% | NR | KM | 7/13 | OS |
| Liang et al. (54) | China | 57 | III–IV | Mean 5 years | Serum | ELISA | >455.61 ng/L | NR | Km | 6/12 | RFS |
| Pan et al. (47) | China | 128 | II–IV | Median 116 months | Tissue | IHC | >25% | NR | M | 8/16 | OS/DFS/ RFS/MFS |
| Kim et al. (50) | Korea | 69 | I–IV | Median 54 months | Tissue | IHC | Score | 200× | M | 8/15 | OS |
| Lv et al. (53) | China | 306 | I–IV | >36 months | Serum | ELISA | >387.0 ng/L | NR | KM | 6/12 | OS/MFS |
| Chang et al. (57) | China | 132 | I–IV | NR | Serum | ELISA | >14.4 pg/mL | NR | KM | 5/12 | OS |
| Kurnianda et al. (55) | Indonesian | 30 | III–IV | Median 16 months | Tissue/ serum | IHC/ELISA | >25%/≥ 834 pg/ml | NR | KM | 7/13 | PFS |
| Segawa et al. (45) | Japan | 76 | I–IV | Median 28.9 months | Tissue | IHC | Score | NR | KM | 7/12 | OS |
| Li et al. (48) | China | 188 | I–IV | NR | Tissue | IHC | >10% | 100× | M | 8/14 | OS |
| Xueguan et al. (42) | China | 59 | II–IV | Median 63 months | Tissue | IHC | >10% | 200× | M | 7/15 | OS/PFS |
| Zhao et al. (39) | China | 66 | I–IV | Median 41 months | Tissue | IHC | >5% | 400× | KM | 5/14 | OS |
| Parikh et al. (46) | USA | 106 | I–II | Median 9.9 years | Tissue | IHC | >25% | NR | M | 7/15 | OS/PFS |
| Sha and He (44) | China | 127 | I–IV | Median 67.5 months | Tissue | IHC | Score | 200× | KM | 4/13 | OS |
| Krishna et al. (49) | India | 64 | I–IV | NR | Tissue | IHC | >25% | 400× | KM | 5/12 | OS |
| Shi et al. (43) | China | 62 | I–IV | >3 years | Tissue | IHC | >10% | 400× | KM | 4/9 | OS |
| Guo et al. (56) | China | 59 | I–IV | Median 36.3 months | Tissue/ serum | IHC/ ELISA | >25% /466.78 ng/L | 400× | M | 6/14 | PFS |
| Hui et al. (51) | China | 90 | II–IV | Median 4.13 years | Tissue | IHC | >25% | 400× | KM | 6/14 | OS/ PFS |
| Zhang et al. (41) | China | 75 | I–IV | >4 years | Tissue | IHC | >10% | 400× | KM | 5/13 | OS |
ELISA, enzyme linked immunosorbent assay; IHC, immunohistochemistry; KM, Kaplan–Meier method; M, multivariate analysis; MFS, metastasis-free survival; NOS, Newcastle-Ottawa Scale; OS, overall survival; PFS, progression-free survival; REMARK, REporting recommendations for tumor MARKer prognostic studies; VEGF, vascular endothelial growth factor.